🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT06725823
Recruiting Not applicable

Therapeutic Effect of Shoulder Anterior Capsular Block Versus Suprascapular Nerve Block in Patients With Frozen Shoulder

NCT06725823 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-01-10
Last updated
2026-05-06

Condition(s) studied

Frozen Shoulder

Investigational drug(s) / intervention(s)

suprascapular nerve block groupshoulder anterior capsular block group

suprascapular nerve block group: A volume of (10 ml) of 2% lidocaine (7ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) will be injected to both groups.

shoulder anterior capsular block group: A volume of (10ml) of 2% lidocaine (7ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40mg) will be injected to both groups.

Study summary

he study will include 50 patients with frozen shoulder with no healthy volunteer , Patients in this study will be randomized into two groups suprascapular nerve block and Shoulder anterior capsular block

Eligibility

Sex
ALL
Min age
19 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Age above 18 years. * Both sexes, males and females. * History of complaint \>6 weeks * Restricted shoulder movement unilaterally in at least 2 planes including abduction, external rotation, and internal rotation and restricted passive movement. Exclusion Criteria: * Patient refusal. * -Allergy to local anaesthetics. * -Infection at the site of injection . * -Coagulopathy * -Prolonged opioid medication * -Pregnancy * -Acute trauma, fracture of the shoulder * People who had received an intra-articular shoulder injection within the last 6 months. * Patients with tendon tear

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sohag university Sohag Egypt Recruiting

More Sohag University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06725823 on ClinicalTrials.gov ↗ ← All trials in Egypt